# INmune Bio (INMB) — Analyst Forecast

INMB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/inmb/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 3 | 0 | 0 | 3 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Mar 11, 2026 | LUCID CAPITAL MARKETS | Upgraded | Neutral → Buy | $9.00 |
| Jul 2, 2025 | Maxim Group | Maintained | Buy | $8.00 |
| Jul 1, 2025 | BTIG | Downgraded | Buy → Neutral | — |
| Jul 1, 2025 | Scotiabank | Downgraded | Sector Outperform → Sector Underperform | $0.60 |
| Feb 13, 2025 | Maxim Group | Maintained | Buy | $30.00 |
| Feb 11, 2025 | Scotiabank | Maintained | Sector Outperform | $23.00 |
| Oct 21, 2024 | Alliance Global Partners | Initiated Coverage | Buy | $20.00 |
| Sep 27, 2024 | Raymond James | Initiated Coverage | Outperform | $18.00 |
| Aug 22, 2024 | Scotiabank | Initiated Coverage | Sector Outperform | $22.00 |

## Frequently Asked Questions

### Is INMB a buy, sell, or hold?

Analysts covering INmune Bio currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on INMB?

On Mar 11, 2026, LUCID CAPITAL MARKETS upgraded INmune Bio to Buy with a price target of $9.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).